Identification of early-stage breast cancer with minimal risk of recurrence by Breast Cancer Index

Researchers evaluated the prognostic ability of the breast cancer index (BCI) to identify patients at a minimal risk of 10-year distant recurrence who are unlikely to benefit from adjuvant endocrine therapy. They found that the adjusted BCI model identified women with early-stage, HR+ N0 breast cancer who are at a minimal risk of distant recurrence who may consider de-escalating adjuvant endocrine therapy.